STS-01
Mild to Moderate (Patchy) Alopecia Areata
Phase 2Active
Key Facts
About Soterios Pharma
Soterios Pharma is a private, clinical-stage biotech developing topical dermatology treatments, with a lead program (STS-01) for mild-to-moderate alopecia areata that has completed a Phase II trial. The company's strategy centers on repurposing or optimizing mechanisms with established safety profiles to create convenient, topical therapies for underserved dermatology indications. Led by an experienced team with pharmaceutical industry and startup expertise, and advised by notable figures including Shire's founder, Soterios is positioned to address a significant market gap where current systemic therapies like JAK inhibitors have limitations.
View full company profile